AKT1/AKT3 (Ab-437/434) Antibody

What is AKT1/AKT3 (Ab-437/434) Antibody and what specific epitope does it recognize?

The AKT1/AKT3 (Ab-437/434) Antibody is a rabbit polyclonal antibody that recognizes endogenous levels of total AKT1/AKT3 protein. It was developed using a synthesized non-phosphopeptide derived from human AKT1/3 around the phosphorylation site of tyrosine 437/434, specifically targeting the amino acid sequence T-R-Y(p)-F-D . This antibody was affinity-purified from rabbit antiserum using epitope-specific immunogen chromatography .

Western blot analysis with this antibody shows detection of a protein band at approximately 56 kDa when tested with extracts from A549 cells . The specificity of the antibody is demonstrated by the ability of the synthesized immunogen peptide to block these protein bands in control experiments .

What are the validated applications for AKT1/AKT3 (Ab-437/434) Antibody?

According to technical specifications, this antibody has been validated for the following applications:

The antibody is particularly suitable for Cell-Based ELISA protocols that allow for the detection of target proteins and monitoring the effects of various stimulation conditions on protein expression in different cell lines . For Western blot applications, the recommended dilution range provides flexibility for optimization based on specific experimental conditions and detection systems.

What is the biological relevance of AKT1 and AKT3 in cellular signaling?

AKT1 is one of three closely related serine/threonine-protein kinases (AKT1, AKT2, and AKT3) collectively referred to as AKT kinase. These proteins regulate numerous cellular processes including:

• Metabolism

• Cell proliferation

• Cell survival

• Growth

• Angiogenesis

This regulation occurs through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported, though isoform specificity hasn't been determined for most .

Functionally, AKT plays a critical role in glucose metabolism by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. Additionally, it phosphorylates PTPN1 at 'Ser-50', which negatively modulates its phosphatase activity, preventing dephosphorylation of the insulin receptor and sustaining insulin signaling .

How can researchers differentiate between AKT1 and AKT3 isoforms in experimental systems?

Differentiating between AKT1 and AKT3 isoforms presents a significant challenge in experimental systems as they share considerable sequence homology, particularly in the regions surrounding the Tyr437/434 phosphorylation sites. When using the AKT1/AKT3 (Ab-437/434) Antibody, researchers should implement the following strategies:

• Complementary approaches: Combine the use of this antibody with isoform-specific antibodies in parallel samples to confirm the identity of detected proteins.

• Genetic manipulation: Utilize siRNA knockdown or CRISPR/Cas9 gene editing of AKT1 or AKT3 individually to verify antibody specificity and distinguish between the isoforms.

• Cell type selection: Choose experimental cell lines with known expression patterns of AKT isoforms. For example, certain cancer cell lines may preferentially express one isoform over others.

• Mass spectrometry validation: For definitive isoform identification, immunoprecipitate with the AKT1/AKT3 antibody followed by mass spectrometry analysis to distinguish between the isoforms based on unique peptide sequences .

• Phosphorylation state analysis: Since the antibody targets a region around a phosphorylation site, compare results with phospho-specific AKT antibodies to determine activation states of different isoforms .

What are the optimal conditions for using AKT1/AKT3 (Ab-437/434) Antibody in Western Blotting experiments?

Based on the available technical information, researchers should consider the following parameters for optimal Western Blotting results:

For optimal results with the AKT1/AKT3 (Ab-437/434) Antibody, ensure proper sample handling to preserve protein integrity. The antibody has been successfully used with A549 cells as demonstrated in validation studies . If signal intensity is an issue, longer exposure times or signal enhancement systems may be employed.

How can the AKT1/AKT3 (Ab-437/434) Antibody be utilized in cell-based ELISA experiments?

The Cell-Based ELISA approach provides a powerful tool for quantitative assessment of AKT1/AKT3 expression and its modulation in response to treatments. Based on the LSBio Cell-Based ELISA Kit protocols, researchers should consider the following methodology:

• Cell preparation: Seed cells in 96-well plates at approximately 30,000 cells per well for adherent cells like HeLa. For suspension cells, pre-coat plates with 10 μg/ml Poly-L-Lysine .

• Assay sensitivity: The assay can detect AKT1/3 expression in as few as 5,000 HeLa cells .

• Fixation and permeabilization: After treatment, fix cells with 4% formaldehyde and permeabilize with 0.5% Triton X-100 .

• Antibody concentration: Use primary antibody (AKT1/AKT3 Ab-437/434) at the manufacturer's recommended dilution, typically included in the kit protocol .

• Detection system: Employ an HRP-conjugated secondary antibody (anti-rabbit IgG) followed by colorimetric substrate addition .

• Normalization: For accurate quantification, normalize results using:

  • Anti-GAPDH antibody as an internal control

  • Crystal Violet whole-cell staining to normalize for cell number

  • Comparison with non-phosphorylated AKT antibody when studying phosphorylation

This method allows for high-throughput screening of compounds that may affect AKT signaling and provides a complementary approach to traditional Western blotting.

What experimental controls should be included when using AKT1/AKT3 (Ab-437/434) Antibody?

For rigorous research with the AKT1/AKT3 (Ab-437/434) Antibody, the following controls are essential:

• Positive control: Include lysates from cells known to express AKT1/AKT3, such as A549 cells, which have been validated in technical documentation .

• Negative control:

  • Omission of primary antibody while maintaining secondary antibody

  • Use of pre-immune serum or isotype-matched IgG

  • When possible, AKT1/AKT3 knockout or knockdown samples

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide (T-R-Y(p)-F-D) to confirm specificity, as documented in validation studies .

• Loading control: Use antibodies against housekeeping proteins such as GAPDH to normalize for protein loading variations .

• Treatment controls: Include samples treated with AKT pathway activators (e.g., insulin) or inhibitors to demonstrate expected biological responses.

• Cross-reactivity testing: If working with species other than human or mouse (the validated reactivity species), perform validation tests in your specific model .

Proper experimental controls not only validate antibody performance but also provide critical context for interpreting experimental results, particularly when studying complex signaling pathways like those involving AKT.

How can researchers troubleshoot weak or non-specific signals when using AKT1/AKT3 (Ab-437/434) Antibody?

When encountering issues with signal detection or specificity, consider the following troubleshooting strategies:

For optimal detection of phosphorylated forms, include both phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride) in lysis buffers and use phospho-specific positive controls to verify detection sensitivity .

If using the antibody in cell-based assays, optimize cell density and fixation conditions. The documentation indicates that 30,000 HeLa cells per well provide optimal results for AKT1/3 detection in 96-well formats .

How can AKT1/AKT3 (Ab-437/434) Antibody be applied in cancer research studies?

The AKT1/AKT3 (Ab-437/434) Antibody offers significant utility in cancer research due to the critical role of AKT signaling in tumorigenesis, progression, and therapy resistance. Researchers can apply this antibody in several cancer research contexts:

• Biomarker analysis: Assess AKT1/AKT3 expression levels in different cancer types and correlate with clinical parameters or treatment outcomes.

• Drug screening: Evaluate the effects of novel therapeutic compounds on AKT signaling pathways using cell-based ELISA or Western blot approaches.

• Resistance mechanisms: Investigate whether altered AKT1/AKT3 expression or phosphorylation contributes to resistance against targeted therapies or conventional chemotherapeutics.

• Pathway cross-talk: Study interactions between AKT signaling and other oncogenic pathways by combining this antibody with markers of related signaling networks.

• AKT isoform-specific functions: Use this antibody alongside isoform-specific reagents to delineate the distinct roles of AKT1 versus AKT3 in specific cancer contexts.

Research has shown that AKT isoforms may have context-dependent roles in cancer, with AKT1 and AKT3 sometimes demonstrating opposing functions in migration and invasion of certain cancer types. This antibody can help elucidate these complex relationships .

What is the significance of tyrosine phosphorylation at positions 437/434 in AKT1/AKT3 function?

While the AKT1/AKT3 (Ab-437/434) Antibody recognizes the region around the tyrosine phosphorylation sites at positions 437/434, it's important to understand the functional significance of these sites:

• Regulatory mechanism: Tyrosine phosphorylation at these sites represents a less-studied regulatory mechanism compared to the well-characterized threonine (Thr308) and serine (Ser473) phosphorylation sites of AKT1.

• Kinase activity modulation: Phosphorylation at these tyrosine residues may modulate AKT kinase activity independently or in conjunction with the canonical phosphorylation sites.

• Protein-protein interactions: These sites may serve as docking sites for SH2 domain-containing proteins, potentially expanding the repertoire of AKT signaling partners.

• Cross-pathway regulation: Tyrosine phosphorylation could represent points of cross-regulation between receptor tyrosine kinase pathways and the PI3K/AKT signaling axis.

• Isoform-specific functions: Differences in the regulation of tyrosine phosphorylation between AKT1 and AKT3 may contribute to their distinct biological roles.

Researchers using this antibody should consider combining it with phospho-specific antibodies against the canonical regulatory sites (Thr308, Ser473) to gain a more complete understanding of AKT activation states in their experimental systems .

What storage and handling practices ensure optimal antibody performance?

Proper storage and handling of the AKT1/AKT3 (Ab-437/434) Antibody are critical for maintaining its performance over time:

• Storage temperature: Upon receipt, store the antibody at -20°C or -80°C to maintain stability .

• Avoid freeze-thaw cycles: Repeated freeze-thaw cycles can diminish antibody activity. Prepare small aliquots for single use upon receipt .

• Working solution preparation: When preparing working dilutions, use fresh buffer systems and maintain cold temperatures to prevent degradation.

• Formulation compatibility: The antibody is provided in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide, and 50% glycerol . Ensure that experimental buffers are compatible with this formulation.

• Contamination prevention: Use sterile technique when handling the antibody to prevent microbial contamination, which can degrade antibody performance.

• Transportation: When transporting between laboratories or to core facilities, maintain cold chain to preserve activity.

• Documentation: Maintain records of antibody lot numbers, receipt dates, and aliquot preparation dates to track performance changes over time.

Following these practices will help ensure consistent performance in experimental applications and maximize the useful life of the antibody.

How should researchers validate AKT1/AKT3 (Ab-437/434) Antibody for new experimental systems?

When adapting the AKT1/AKT3 (Ab-437/434) Antibody to new experimental systems or models, thorough validation is essential:

• Species cross-reactivity: While validated for human and mouse samples , testing in other species requires empirical validation using appropriate positive controls.

• Application-specific validation:

  • For Western blotting: Confirm band size, specificity, and linearity of signal

  • For ELISA: Establish detection limits and standard curves

  • For immunocytochemistry/immunohistochemistry: Optimize fixation, permeabilization, and antigen retrieval methods

• Cell/tissue-specific considerations: Expression levels of AKT1/AKT3 vary across tissues and cell types. Establish baseline expression in your system before experimental manipulation.

• Validation criteria:

  • Specificity: Use knockout/knockdown controls or peptide competition

  • Sensitivity: Determine minimum detectable protein amounts

  • Reproducibility: Ensure consistent results across multiple experiments

  • Dynamic range: Confirm ability to detect both increases and decreases in target protein

• Protocol optimization: Systematically test variables such as antibody concentration, incubation time/temperature, and blocking reagents to determine optimal conditions for your specific application.

• Results reporting: Document validation steps thoroughly to support publication requirements and reproducibility standards in the scientific literature.

By implementing these validation approaches, researchers can ensure reliable and interpretable results when using the AKT1/AKT3 (Ab-437/434) Antibody in novel experimental systems .